Stocklytics Platform
Asset logo for symbol FHTX
Foghorn Therapeutics
Asset logo for symbol FHTX


Key Stats
Prev. Close$5.87
Next Earnings Date-
Dividend Yield %-
Market Cap$293.79M
PE Ratio-
Day Range5.70
52 Week Range2.70
P/B Ratio10.71
Operating M. %-558.30%
Earnings Growth %9.60%
EBITDA Margin %-290.90%
ROE %-470.38%
Gross Profit$25.49M
Total Debt$42.97M
P/S Ratio9.2x
Enterprise to EBITDA-1.21
Profit Margin-274.23%
Debt/Equity Ratio-
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis


Summarizing what the indicators are suggesting.

Strong Buy
Strong Sell
Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Strong Sell

Stock Performance

US Healthcare Sectorarrow_drop_up0.81%
US Marketarrow_drop_up1.43%
FHTX / Market
FHTX exceeded the US Market which returned 1.43% over the last twenty four hours.
FHTX / Healthcare Sector
FHTX exceeded the US Healthcare sector which returned 0.81% over the last twenty four hours.

Foghorn Therapeutics (FHTX) Statistics

Foghorn Therapeutics Inc (FHTX) is a biotechnology company focused on the discovery and development of novel therapeutics targeting the chromatin regulatory system. With a mission to unlock the therapeutic potential of this system, Foghorn is utilizing its proprietary Gene Traffic Control platform to identify and target key regulatory nodes within the chromatin network. By targeting these nodes, Foghorn aims to modulate gene expression and address a wide range of diseases, including cancer and neurological disorders.

The valuation metrics of Foghorn Therapeutics Inc (FHTX) reflect the market's perception of the company's worth. These metrics include the company's market capitalization, enterprise value, and price-to-earnings ratio. The market capitalization represents the total value of the company's outstanding shares, while the enterprise value takes into account the company's total debt and cash reserves. The price-to-earnings ratio compares the company's stock price to its earnings per share and provides an indication of how investors perceive the company's future earnings potential. These valuation metrics can be used by investors to assess the relative value of FHTX compared to its peers in the biotechnology sector.

add Foghorn Therapeutics  to watchlist

Keep an eye on Foghorn Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

How has Foghorn Therapeutics (FHTX) stock's performance compared to its sector and the market over the past year?

Over the past year, Foghorn Therapeutics (FHTX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 23.49%, Foghorn Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 52.38%, it has fallen short of the market average. This comparison highlights Foghorn Therapeutics 's performance relative to both its sector and the overall market over the last year.

What is the PE ratio of Foghorn Therapeutics (FHTX) stock?

The PE ratio for Foghorn Therapeutics (FHTX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

What is the EPS of Foghorn Therapeutics (FHTX) stock?

The Earnings Per Share (EPS) for Foghorn Therapeutics (FHTX), calculated on a diluted basis, is -$2.2. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

What is the operating margin of Foghorn Therapeutics (FHTX) stock?

The operating margin for Foghorn Therapeutics (FHTX) is -558.3%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

What is the EBITDA of Foghorn Therapeutics (FHTX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Foghorn Therapeutics (FHTX) is -$99.36M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

How much debt does Foghorn Therapeutics (FHTX) have?

Foghorn Therapeutics (FHTX) has a total debt of $42.98M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$36.27M.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level